MedTrace Logo

Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C

NCT04159246 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-11-12

No results posted yet for this study

Summary

The purpose of this study is to prospectively evaluate the value of Optical coherence tomography angiography (OCT-A) for the of detection of suspected retinal complications With Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection

Conditions

  • HCV Infection

Interventions

DEVICE

Optical coherence tomography angiography

Recent Optical coherence tomography angiography "OCT-A" will be performed to all patients before Treatment Administration. * Examination will be performed using Optovue AngioVue® "Optovue, Inc., Fremont, CA", which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps. * The patient will be examined before and after finishing the treatment course

DRUG

Sofosbuvir (Sovaldi)

Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months

Sponsors & Collaborators

  • Mohamed Saad

    lead OTHER

Principal Investigators

  • Hany E Elmekewy, MD · Cairo University

  • Magada S Abdelaziz, MD · Cairo University

  • Yomna A Abdelwahab, MD · Cairo University

  • Mai I Mehrez, MD · National Hepatology & Tropical Medicine Research Institute

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-10
Primary Completion
2019-11-30
Completion
2019-11-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159246 on ClinicalTrials.gov